Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction

OBJECTIVE: Chronic heart failure with reduced ejection fraction (HF-REF) represents a major public health issue and is associated with considerable morbidity and mortality. We evaluated the cost-effectiveness of sacubitril/valsartan (formerly LCZ696) compared with an ACE inhibitor (ACEI) (enalapril)...

Descripción completa

Detalles Bibliográficos
Autores principales: McMurray, John J V, Trueman, David, Hancock, Elizabeth, Cowie, Martin R, Briggs, Andrew, Taylor, Matthew, Mumby-Croft, Juliet, Woodcock, Fionn, Lacey, Michael, Haroun, Rola, Deschaseaux, Celine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Health Care Delivery, Economics and Global Health Care
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992367/
https://www.ncbi.nlm.nih.gov/pubmed/29269379
http://dx.doi.org/10.1136/heartjnl-2016-310661

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992367/
https://www.ncbi.nlm.nih.gov/pubmed/29269379
http://dx.doi.org/10.1136/heartjnl-2016-310661

Ejemplares similares